Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00902304 · ClinicalTrials.gov registry record · Phase 4
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,337
- Enrollment target
NCT00902304 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,337 participants.
The verdict
NCT00902304, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,337 participants
- Enrollment target
Study Summary
This study will assess the efficacy of an intensive blood pressure management strategy compared to usual care in a primary care (general practice) setting.
Interventions
- DRUG Valsartan
- DRUG Usual care
- DRUG Valsartan and hydrochlorothiazide (HCTZ) - monotherapy
- DRUG Valsartan and amlodipine
- DRUG Valsartan and hydrochlorothiazide (HCTZ) - combination arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,337 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00902304
The ClinicalTrials.gov registry entry for NCT00902304 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2,337 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Valsartan is the first listed.
NCT00902304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00902304 about?
NCT00902304 is a clinical study titled "Valsartan Intensified Primary Care Reduction of Blood Pressure Study". This study will assess the efficacy of an intensive blood pressure management strategy compared to usual care in a primary care (general practice) setting.
What is the current status of trial NCT00902304?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,337 participants. The study started on 2009-07. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00902304?
The interventions under investigation include: Valsartan (DRUG), Usual care (DRUG), Valsartan and hydrochlorothiazide (HCTZ) - monotherapy (DRUG), Valsartan and amlodipine (DRUG), Valsartan and hydrochlorothiazide (HCTZ) - combination arm (DRUG).
Who is sponsoring clinical trial NCT00902304?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.